Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 121 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Follow-Up Questions
Kodiak Sciences Inc のCEOは誰ですか？
Dr. Victor Perlroth は Kodiak Sciences Inc の Chairman of the Board で、2009 から在籍しています。
KOD の株価パフォーマンスは？
KOD の現在の価格は $18.68 で、最終取引日から 0.02% decreased 変動しました。
Kodiak Sciences Inc の主な事業テーマや業界は？
Kodiak Sciences Inc は Biotechnology 業界、セクターは Health Care に属しています。
